BOT.AU BOTANIX PHARMACEUTICALS LTD
Market Closed 05-10 16:12:00 AEST
0.28
+0.00
-1.79%
High0.29Low0.27Vol6.62M
Open0.29D1 Closing0.28Amplitude7.14%
Mkt Cap433.16MTradable Cap365.31MTotal Shares1.58B
T/O1.83MT/O Rate0.50%Tradable Shares1.33B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Could ASX cannabis shares be set for a smoking hot rebound?
MotleyFool  ·  05-01
Could ASX cannabis shares be set for a smoking hot rebound?
We're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Simply Wall St.  ·  05-01
We're Keeping An Eye On Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
BRIEF-Botanix Pharmaceuticals Appoints Graeme Morissey CFO
Reuters  ·  03-26
BRIEF-Botanix Pharmaceuticals Appoints Graeme Morissey CFO
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
Simply Wall St.  ·  03-21
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
BRIEF-Botanix Pharmaceuticals Posts Loss For Half-Year Attributable A$5.5 Million
Reuters  ·  02-28
BRIEF-Botanix Pharmaceuticals Posts Loss For Half-Year Attributable A$5.5 Million
ASX to rise, S&P 500 hits fresh record high + Inghams, IAG and QBE to report
LiveWire  ·  02-16
ASX to rise, S&P 500 hits fresh record high + Inghams, IAG and QBE to report
If you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 now
MotleyFool  ·  01-24
If you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 now
Botannix Pharmaceuticals’ resubmission of Sofdra NDA accepted by FDA
The Market Herald  ·  01-22
Botannix Pharmaceuticals’ resubmission of Sofdra NDA accepted by FDA
BRIEF-Botanix Pharmaceuticals Says NDA Resubmission Accepted
Reuters  ·  01-22
BRIEF-Botanix Pharmaceuticals Says NDA Resubmission Accepted
12 stocks with game-changing catalysts in 2024
LiveWire  ·  01-18
12 stocks with game-changing catalysts in 2024
BRIEF-Botanix Pharmaceuticals Says Completed Resubmission Of New Drug Application For Sofdra
Reuters  ·  2023-12-21
BRIEF-Botanix Pharmaceuticals Says Completed Resubmission Of New Drug Application For Sofdra
Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024
The Market Herald  ·  2023-12-14
Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024
BRIEF-Botanix Pharmaceuticals Says FDA Confirms Approach To Sofdra™ NDA Resubmission And Materials Required
Reuters  ·  2023-12-04
BRIEF-Botanix Pharmaceuticals Says FDA Confirms Approach To Sofdra™ NDA Resubmission And Materials Required
FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan
The Market Herald  ·  2023-12-04
FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan
Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities
The Market Herald  ·  2023-12-01
Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Introduction

Company Name.
BOTANIX PHARMACEUTICALS LTD
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Botanix Pharmaceuticals Limited, a clinical stage cannabinoid therapeutics company, develops therapeutics for serious skin diseases in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; BTX 1701, a novel product for mild acne; and BTX 1801, a novel antimicrobial. The company is based in North Perth, Australia.
Issue price:
--